Recombinant 2019-nCoV Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala419) of 2019-ncov Nucleocapsid (Accession #QHD43423.2) fused with an 6xHis tag at the N-terminus.
Reinheit
> 95 % by SDS-PAGE,> 95 % by HPLC.
Sterilität
0.22 μm filtered
Endotoxin-Niveau
< 1.0 EU/μg of the protein by LAL method.
Biological Activity Comment
1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Nucleocapsid at 2 μg/mL (100 μL/well) can bind Anti-Nucleocapsid antibody with a linear range of 0.12-1.64 ng/mL.< /br>2.Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 envelope Protein at 2 μg/mL (100 μL/well) can bind Recombinant SARS-CoV-2 Nucleocapsid protein, the EC50 of Recombinant SARS-CoV-2 Nucleocapsid protein is 41.10 ng/mL.
SARS-CoV-2 N
Spezies: SARS Coronavirus-2 (SARS-CoV-2)
Wirt: HEK-293 Cells
Recombinant
>90 % as determined by SDS-PAGE.
Active
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Supplied as a 0.22 μm filtered solution in 20 mM Tris, 500 mM NaCl, 0.1 mM EDTA, 10 % glycerol, pH 8.0.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-80 °C
Informationen zur Lagerung
This product is stable at ≤ -70°C for up to 1 year from the date of receipt.|For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature.